需住院的COVID-19肺炎哮喘患者的特征与结局
法国Bicêtre医院2020年3月15日至4月15日前瞻性队列随访纳入768例住院SARS-CoV-2感染患者,其中37例(4.8%)有哮喘史。哮喘患者均未出现哮喘急性发作,11例(30%)入住ICU,3例死亡(8.1%),死亡均伴合并症。哮喘在需住院的重症COVID-19肺炎患者中未见比例升高,不良结局主要见于有重大合并症者。
要点
- 住院COVID-19患者中哮喘史占4.8%,未见比例升高。
- 哮喘患者均未出现哮喘急性发作。
- 不良结局主要见于有重大合并症者。
核心结论
- 哮喘患者在需住院的SARS-CoV-2重症肺炎患者中未见比例升高。
- 最差结局主要见于有重大合并症的患者。
研究设计与样本
- 2020年3月15日至4月15日在法国Bicêtre医院开展前瞻性队列随访。
- 纳入所有住院且报告有哮喘史的SARS-CoV-2感染患者。
- 共768例住院患者,其中37例(4.8%)报告有哮喘史,85%曾由呼吸科医生确认。
主要发现
- 哮喘患者以女性为主(70%),非吸烟者占85%,中位年龄54岁(IQR 42–67岁)。
- 无一人出现哮喘急性发作。
- 22例(59%)有重大合并症,31例(84%)BMI≥25 kg·m-2。
- 常见合并症为肥胖(36%)、高血压(27%)和糖尿病(19%)。
- 嗜酸性粒细胞减少为典型生物学特征,中位计数0 cells·mm-3(IQR 0–0 cells·mm-3)。
关键数值与推荐
- 37例(4.8%)住院患者报告有哮喘史。
- 11例(30%)入住ICU,3例死亡(8.1%),死亡均伴合并症。
- 所有患者胸部CT均确诊COVID-19肺炎。
临床怎么用
- 对有哮喘史的COVID-19住院患者,应重点评估和管理重大合并症。
- 哮喘史本身不应视为需住院COVID-19肺炎患者比例升高或哮喘急性发作的标志。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Viral respiratory infections are the main causes of asthma exacerbation. The susceptibility of patients with asthma to develop an exacerbation when they present with severe pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is unknown. The objective of this study was to investigate the characteristics and outcomes of asthmatic patients with coronavirus disease 2019 (COVID-19) pneumonia who required hospitalisation during the spring 2020 outbreak in Paris, France. METHODS: A prospective cohort follow-up was carried out from 15 March to 15 April 2020 in Bicêtre Hospital, University Paris-Saclay, France. All hospitalised patients with a SARS-CoV-2 infection who reported a history of asthma were included. RESULTS: Among 768 hospitalised patients, 37 (4.8%) reported a history of asthma, which had been previously confirmed by a pulmonologist in 85% of cases. These asthmatic patients were mainly female (70%) and nonsmokers (85%), with a median age of 54 years (interquartile range (IQR) 42-67 years). None of them presented with an asthma exacerbation. 22 (59%) had major comorbidities and 31 (84%) had a body mass index ≥25 kg·m-2. The most common comorbidities were obesity (36%), hypertension (27%) and diabetes (19%). All patients had a confirmed diagnosis of COVID-19 pneumonia on computed tomography of the chest. Eosinopenia was a typical biological feature with a median count of 0 cells·mm-3 (IQR 0-0 cells·mm-3). 11 patients (30%) were admitted into the intensive care unit, with three deaths (8.1%) occurring in the context of comorbidities. CONCLUSION: Asthma patients were not overrepresented among those with severe pneumonia due to SARS-CoV-2 infection who required hospitalisation. The worst outcomes were observed mainly in patients with major comorbidities.
引用
- Beurnier A, Jutant EM, Jevnikar M, et al. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. Eur Respir J. 2020. PMID: 32732333. doi:10.1183/13993003.01875-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。